Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
Belite Bio (NASDAQ: BLTE), a San Diego-based clinical stage biopharmaceutical company, has announced the availability of its annual report on Form 20-F for the fiscal year ended December 31, 2024. The report, which includes audited consolidated financial statements, was filed with the Securities and Exchange Commission on March 17, 2025, and can be accessed through the company's website at belitebio.com. Shareholders can request a free hard copy of the annual report.
Belite Bio (NASDAQ: BLTE), un'azienda biofarmaceutica in fase clinica con sede a San Diego, ha annunciato la disponibilità del suo rapporto annuale sul modulo 20-F per l'anno fiscale conclusosi il 31 dicembre 2024. Il rapporto, che include bilanci consolidati certificati, è stato depositato presso la Securities and Exchange Commission il 17 marzo 2025 ed è accessibile attraverso il sito web dell'azienda all'indirizzo belitebio.com. Gli azionisti possono richiedere una copia cartacea gratuita del rapporto annuale.
Belite Bio (NASDAQ: BLTE), una compañía biofarmacéutica en etapa clínica con sede en San Diego, ha anunciado la disponibilidad de su informe anual en el Formulario 20-F para el año fiscal que finalizó el 31 de diciembre de 2024. El informe, que incluye estados financieros consolidados auditados, fue presentado a la Comisión de Valores y Bolsa el 17 de marzo de 2025 y se puede acceder a través del sitio web de la empresa en belitebio.com. Los accionistas pueden solicitar una copia impresa gratuita del informe anual.
Belite Bio (NASDAQ: BLTE), 샌디에이고에 본사를 둔 임상 단계의 생물 제약 회사,는 2024년 12월 31일 종료된 회계 연도의 20-F 양식 연례 보고서의 가용성을 발표했습니다. 감사된 연결 재무제표를 포함하는 이 보고서는 2025년 3월 17일 증권 거래 위원회에 제출되었으며, 회사 웹사이트 belitebio.com을 통해 접근할 수 있습니다. 주주들은 연례 보고서의 무료 인쇄본을 요청할 수 있습니다.
Belite Bio (NASDAQ: BLTE), une entreprise biopharmaceutique en phase clinique basée à San Diego, a annoncé la disponibilité de son rapport annuel sur le formulaire 20-F pour l'exercice clos le 31 décembre 2024. Le rapport, qui comprend des états financiers consolidés audités, a été déposé auprès de la Securities and Exchange Commission le 17 mars 2025 et peut être consulté sur le site Web de l'entreprise à l'adresse belitebio.com. Les actionnaires peuvent demander un exemplaire papier gratuit du rapport annuel.
Belite Bio (NASDAQ: BLTE), ein biopharmazeutisches Unternehmen in klinischer Phase mit Sitz in San Diego, hat die Verfügbarkeit seines Jahresberichts im Formular 20-F für das am 31. Dezember 2024 endende Geschäftsjahr bekannt gegeben. Der Bericht, der geprüfte konsolidierte Finanzberichte enthält, wurde am 17. März 2025 bei der Securities and Exchange Commission eingereicht und kann über die Unternehmenswebsite belitebio.com abgerufen werden. Aktionäre können eine kostenlose gedruckte Kopie des Jahresberichts anfordern.
- None.
- None.
SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 17, 2025, is available through its website (https://www.belitebio.com). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When did Belite Bio (BLTE) file its 2024 annual report?
How can shareholders access Belite Bio's (BLTE) 2024 annual report?
What period does Belite Bio's (BLTE) latest annual report cover?
What type of financial statements are included in Belite Bio's (BLTE) 2024 annual report?
